PARIS--(BUSINESS WIRE)--Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of data from a multi-center Phase I/IIa study designed to investigate the safety of Interleukin-7 (IL-7) therapy in chronically HIV-1 infected patients whose CD4 T cell counts remained low despite treatment with anti-retroviral-therapies (HAART). After 48 weeks, patients treated at the higher dose level showed a median increase in CD4 and CD8 T cell counts (cells/microliters) of 75% and 58%, respectively, from baseline levels.
